Literature DB >> 27701988

Effect of particle size on oral bioavailability of darunavir-loaded solid lipid nanoparticles.

Jagruti Desai1, Hetal Thakkar1.   

Abstract

The present investigation aimed to study the effect of particle size of solid lipid nanoparticles (SLNs) on oral bioavailability of darunavir. High pressure homogenisation technique was used to prepare SLNs. Three different sized SLNs loaded with darunavir were developed with mean particle sizes of around 100 nm, 200 nm and 500 nm, respectively. The in vivo pharmacokinetics in rats showed a significant increase in oral bioavailability of darunavir from all the three formulations in comparison to plain drug suspension and reference tablet. The results revealed insignificant difference between SLNs of 100 and 200 nm and these had significantly higher bioavailability in comparison to SLNs of 500 nm. However, more number of homogenisation cycles is required for obtaining 100 nm and thus we selected 200 nm as an optimum size for oral bioavailability enhancement of darunavir. The optimised SLN formulation was stable for a period of 6 months at 25 ± 2 °C/60 ± 5% relative humidity (RH).

Entities:  

Keywords:  Oral bioavailability; high pressure homogenisation; protease inhibitor

Mesh:

Substances:

Year:  2016        PMID: 27701988     DOI: 10.1080/02652048.2016.1245363

Source DB:  PubMed          Journal:  J Microencapsul        ISSN: 0265-2048            Impact factor:   3.142


  8 in total

Review 1.  Nanotechnology approaches for delivery of cytochrome P450 substrates in HIV treatment.

Authors:  Yuqing Gong; Pallabita Chowdhury; Prashanth K B Nagesh; Theodore J Cory; Chelsea Dezfuli; Sunitha Kodidela; Ajay Singh; Murali M Yallapu; Santosh Kumar
Journal:  Expert Opin Drug Deliv       Date:  2019-07-24       Impact factor: 6.648

2.  Synthesis and Characterization of Long-Acting Darunavir Prodrugs.

Authors:  Mary G Banoub; Aditya N Bade; Zhiyi Lin; Denise Cobb; Nagsen Gautam; Bhagya Laxmi Dyavar Shetty; Melinda Wojtkiewicz; Yazen Alnouti; JoEllyn McMillan; Howard E Gendelman; Benson Edagwa
Journal:  Mol Pharm       Date:  2019-12-03       Impact factor: 4.939

Review 3.  Genistein as a regulator of signaling pathways and microRNAs in different types of cancers.

Authors:  Zeeshan Javed; Khushbukhat Khan; Jesús Herrera-Bravo; Sajid Naeem; Muhammad Javed Iqbal; Haleema Sadia; Qamar Raza Qadri; Shahid Raza; Asma Irshad; Ali Akbar; Željko Reiner; Ahmed Al-Harrasi; Ahmed Al-Rawahi; Dinara Satmbekova; Monica Butnariu; Iulia Cristina Bagiu; Radu Vasile Bagiu; Javad Sharifi-Rad
Journal:  Cancer Cell Int       Date:  2021-07-21       Impact factor: 6.429

4.  Luminescent PLGA Nanoparticles for Delivery of Darunavir to the Brain and Inhibition of Matrix Metalloproteinase-9, a Relevant Therapeutic Target of HIV-Associated Neurological Disorders.

Authors:  Tiziana Latronico; Federica Rizzi; Annamaria Panniello; Valentino Laquintana; Ilaria Arduino; Nunzio Denora; Elisabetta Fanizza; Serafina Milella; Claudio M Mastroianni; Marinella Striccoli; Maria Lucia Curri; Grazia M Liuzzi; Nicoletta Depalo
Journal:  ACS Chem Neurosci       Date:  2021-11-02       Impact factor: 5.780

5.  Absorption Study of Genistein Using Solid Lipid Microparticles and Nanoparticles: Control of Oral Bioavailability by Particle Sizes.

Authors:  Jeong Tae Kim; Sonia Barua; Hyeongmin Kim; Seong-Chul Hong; Seung-Yup Yoo; Hyojin Jeon; Yeongjin Cho; Sangwon Gil; Kyungsoo Oh; Jaehwi Lee
Journal:  Biomol Ther (Seoul)       Date:  2017-07-01       Impact factor: 4.634

6.  Corneal permeation properties of a charged lipid nanoparticle carrier containing dexamethasone.

Authors:  Junfeng Ban; Yan Zhang; Xin Huang; Guanghan Deng; Dongzhi Hou; Yanzhong Chen; Zhufen Lu
Journal:  Int J Nanomedicine       Date:  2017-02-16

Review 7.  Chitosan-Hyaluronic Acid Nanoparticles for Active Targeting in Cancer Therapy.

Authors:  Lisa Efriani Puluhulawa; I Made Joni; Khaled M Elamin; Ahmed Fouad Abdelwahab Mohammed; Muchtaridi Muchtaridi; Nasrul Wathoni
Journal:  Polymers (Basel)       Date:  2022-08-20       Impact factor: 4.967

8.  Role of nano-lipid formulation of CARP-1 mimetic, CFM-4.17 to improve systemic exposure and response in osimertinib resistant non-small cell lung cancer.

Authors:  Nagavendra Kommineni; Ebony Nottingham; Arvind Bagde; Nilkumar Patel; Arun K Rishi; Satyanarayan R S Dev; Mandip Singh
Journal:  Eur J Pharm Biopharm       Date:  2020-11-18       Impact factor: 5.571

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.